瑞利珠单抗治疗哮喘疗效与安全性的Meta分析

发布时间：2018-04-01 20:31

本文选题：瑞利珠单抗　切入点：抗体　出处：《中国新药与临床杂志》2017年12期

【摘要】：目的系统评价瑞利珠单抗治疗哮喘的疗效和安全性。方法计算机检索Pub Med、EMbase、Clinical Trials.gov、中国知网、万方数据库、维普中文数据库,收集瑞利珠单抗治疗哮喘的临床随机对照试验(RCT),检索时间为建库至2017年2月,同时手工检索相关研究的参考文献,通过改良Jadad量表评分对所纳入的RCT进行偏倚风险评估,及对文献进行质量评价,并通过Rev Man5.3软件进行Meta分析。结果共纳入符合标准的5个RCT研究,总计患者1 666例。Meta分析结果显示:与安慰剂相比,改善患者第1秒用力呼气容积[WMD=0.10,95%CI(0.05,0.15),P=0.000 2],哮喘生活质量调查问卷评分[WMD=0.27,95%CI(0.13,0.42),P=0.000 2],哮喘控制问卷评分[WMD=-0.35,95%CI(-0.38,-0.32),P=0.000 1],减少急救药物的使用[WMD=-0.13,95%CI(-0.31,0.05),P=0.16],不良反应发生率减少[OR=0.62,95%CI(0.50,0.78),P0.000 1],严重不良反应发生率相当[OR=0.81,95%CI(0.56,1.18),P=0.28]。结论瑞利珠单抗治疗哮喘可明显改善患者肺功能、症状和生活质量,且安全有效。
[Abstract]:Objective to evaluate the efficacy and safety of Rilizumab in the treatment of asthma. Methods Pub Medbase Clinical Trials.gov. A randomized controlled trial of RCTA in the treatment of asthma with Rilidzumab was collected. The retrieval time was set up until February 2017. Meanwhile, the references of related studies were manually searched, and the bias risk of the RCT was evaluated by the modified Jadad scale score. The quality of the literature was evaluated, and the Meta analysis was performed by Rev Man5.3 software. The results included 5 RCT studies that met the criteria. A total of 1,666 patients were included in the meta-analysis. The results showed that: compared with placebo, Improve the forced expiratory volume in the first second of the patient [WMD-0.1095 CIQ 0.05 ~ 0.15 P0.0002], the quality of Asthma questionnaire [WMD0.2795CI0.130.42P0.0002], the Asthma Control questionnaire [WMD-0.3595CI-0.38CI-0.32CI-0.32p0.0001], reduce the use of first-aid drugs [WMD-0.1395CI-0.310.05P0.16], reduce the incidence of adverse reactions [OR0.629595CI-0.500.78P0.0001], reduce the incidence of adverse reactions. Conclusion Rilizumab can significantly improve pulmonary function in patients with asthma. Symptoms and quality of life, and safe and effective.
【作者单位】：南昌市第三医院呼吸科;
【分类号】：R562.25

【相似文献】